Literature DB >> 9916847

Left-right axis malformations associated with mutations in ACVR2B, the gene for human activin receptor type IIB.

R Kosaki1, M Gebbia, K Kosaki, M Lewin, P Bowers, J A Towbin, B Casey.   

Abstract

Targeted disruption of the mouse activin receptor type IIB gene (Acvr2b) results in abnormal left-right (LR) axis development among Acvr2b-/- homozygotes [Oh and Li, 1997: Genes Dev 11:1812-1826]. The resulting malformations include atrial and ventricular septal defects, right-sided morphology of the left atrium and left lung, and spleen hypoplasia. Based on these results, we hypothesized that mutations in the type IIB activin receptor gene are associated with some cases of LR axis malformations in humans. We report here characterization of the ACVR2B genomic structure, analysis of ACVR2B splice variants, and screening for ACVR2B mutations among 112 sporadic and 14 familial cases of LR axis malformations. Two missense substitutions have been identified, one of which appears in two unrelated individuals. Neither of these nucleotide changes has been found in 200 control chromosomes. We conclude that ACVR2B mutations are present only rarely among human LR axis malformation cases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9916847     DOI: 10.1002/(sici)1096-8628(19990101)82:1<70::aid-ajmg14>3.0.co;2-y

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  49 in total

Review 1.  The genetics of congenital heart disease.

Authors:  Paul D Grossfeld
Journal:  J Nucl Cardiol       Date:  2003 Jan-Feb       Impact factor: 5.952

Review 2.  The molecular basis of vascular disorders.

Authors:  J A Towbin; B Casey; J Belmont
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

3.  Rare copy number variations in congenital heart disease patients identify unique genes in left-right patterning.

Authors:  Khalid A Fakhro; Murim Choi; Stephanie M Ware; John W Belmont; Jeffrey A Towbin; Richard P Lifton; Mustafa K Khokha; Martina Brueckner
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

4.  N-linked glycosylation of the bone morphogenetic protein receptor type 2 (BMPR2) enhances ligand binding.

Authors:  Jonathan W Lowery; Jose M Amich; Alex Andonian; Vicki Rosen
Journal:  Cell Mol Life Sci       Date:  2013-12-15       Impact factor: 9.261

Review 5.  Follow your gut: relaying information from the site of left-right symmetry breaking in the mouse.

Authors:  Yukio Saijoh; Manuel Viotti; Anna-Katerina Hadjantonakis
Journal:  Genesis       Date:  2014-05-05       Impact factor: 2.487

6.  Identification and functional analysis of ZIC3 mutations in heterotaxy and related congenital heart defects.

Authors:  Stephanie M Ware; Jianlan Peng; Lirong Zhu; Susan Fernbach; Suzanne Colicos; Brett Casey; Jeffrey Towbin; John W Belmont
Journal:  Am J Hum Genet       Date:  2003-12-16       Impact factor: 11.025

7.  Ott1 (Rbm15) is essential for placental vascular branching morphogenesis and embryonic development of the heart and spleen.

Authors:  Glen D Raffel; Gerald C Chu; Jonathan L Jesneck; Dana E Cullen; Roderick T Bronson; Olivier A Bernard; D Gary Gilliland
Journal:  Mol Cell Biol       Date:  2008-11-03       Impact factor: 4.272

8.  Bilateral renal agenesis/hypoplasia/dysplasia (BRAHD): postmortem analysis of 45 cases with breakpoint mapping of two de novo translocations.

Authors:  Louise Harewood; Monica Liu; Jean Keeling; Alan Howatson; Margo Whiteford; Peter Branney; Margaret Evans; Judy Fantes; David R Fitzpatrick
Journal:  PLoS One       Date:  2010-08-25       Impact factor: 3.240

Review 9.  Review of genetic factors in intestinal malrotation.

Authors:  Vicki Martin; Charles Shaw-Smith
Journal:  Pediatr Surg Int       Date:  2010-06-13       Impact factor: 1.827

10.  Laterality disturbance and hypopituitarism. A case report of co-existing situs inversus totalis and combined pituitary hormone deficiency.

Authors:  Z Halász; R Bertalan; J Toke; A Patócs; M Tóth; G Fekete; E Gláz; K Rácz
Journal:  J Endocrinol Invest       Date:  2008-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.